{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:13:23Z","timestamp":1778642003463,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"national Hospital Program of Clinical Research","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00228-021-03153-6","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:03:48Z","timestamp":1620633828000},"page":"1569-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-7447","authenticated-orcid":false,"given":"Sarah","family":"Bitar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Thilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Agrinier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"3153_CR1","doi-asserted-by":"crossref","unstructured":"Sharma K, Kass D (2014) Heart failure with preserved ejection fraction. Circ Res\u00a0115(1):79\u201396","DOI":"10.1161\/CIRCRESAHA.115.302922"},{"issue":"3","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EES van Riet","year":"2016","unstructured":"van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242\u2013252","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"3153_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251\u2013259","journal-title":"N Engl J Med"},{"key":"3153_CR4","doi-asserted-by":"crossref","unstructured":"Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J et al (2015) The hospitalization burden and post-hospitalization mortality risk in heart\u00a0failure with preserved ejection\u00a0fraction: results from the I-PRESERVE trial (Irbesartan in Heart\u00a0Failure\u00a0and Preserved Ejection Fraction). JACC: Heart Failure 3(6):429\u2013441","DOI":"10.1016\/j.jchf.2014.12.017"},{"issue":"8","key":"3153_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18(8):891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ van Veldhuisen","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, B\u00f6hm M, Anker SD, Babalis D, Roughton M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150\u20132158","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"3153_CR7","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345","journal-title":"Eur Heart J"},{"issue":"23","key":"3153_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467","journal-title":"N Engl J Med"},{"issue":"9386","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777\u2013781","journal-title":"Lancet"},{"issue":"15","key":"3153_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"1","key":"3153_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","volume":"126","author":"BA Steinberg","year":"2012","unstructured":"Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP et al (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126(1):65\u201375","journal-title":"Circulation"},{"issue":"6","key":"3153_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.acvd.2012.04.003","volume":"105","author":"A Cohen Solal","year":"2012","unstructured":"Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C et al (2012) Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: The FUTURE survey. Arch Cardiovasc Dis 105(6):355\u2013365","journal-title":"Arch Cardiovasc Dis"},{"issue":"9","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.amjcard.2013.01.276","volume":"111","author":"RJ Goldberg","year":"2013","unstructured":"Goldberg RJ, Gurwitz JH, Saczynski JS, Hsu G, McManus DD, Magid DJ et al (2013) Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]). Am J Cardiol 111(9):1324\u20131329","journal-title":"Am J Cardiol"},{"issue":"1","key":"3153_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","volume":"47","author":"CW Yancy","year":"2006","unstructured":"Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47(1):76\u201384","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3153_CR15","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola V-P et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(12):1574\u20131585","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"3153_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstr\u00f6m U, Filippatos G, Ponikowski P, Zannad F et al (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15(10):1173\u20131184","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"3153_CR17","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2012.14785","volume":"308","author":"LH Lund","year":"2012","unstructured":"Lund LH, Benson L, Dahlstr\u00f6m U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308(20):2108\u20132117","journal-title":"JAMA"},{"issue":"4","key":"3153_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10741-012-9329-8","volume":"18","author":"V Agarwal","year":"2013","unstructured":"Agarwal V, Briasoulis A, Messerli FH (2013) Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 18(4):429\u2013437","journal-title":"Heart Fail Rev"},{"issue":"228","key":"3153_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijcard.2016.11.239","volume":"1","author":"H Fukuta","year":"2017","unstructured":"Fukuta H, Goto T, Wakami K, Ohte N (2017) The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Int J Cardiol 1(228):4\u201310","journal-title":"Int J Cardiol"},{"key":"3153_CR20","doi-asserted-by":"crossref","unstructured":"Bitar S, Agrinier N, Alla F, Rossignol P, Mebazaa A, Thilly N (2019) Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: results from the EPICAL2 cohort study. Pharmacoepidemiol Drug Saf 28(11):1489\u20131500","DOI":"10.1002\/pds.4868"},{"issue":"51","key":"3153_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejim.2017.12.005","volume":"1","author":"A Busson","year":"2018","unstructured":"Busson A, Thilly N, Laborde-Cast\u00e9rot H, Alla F, Messikh Z, Clerc-Urmes I et al (2018) Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: results from the EPICAL2 cohort study. Eur J Intern Med 1(51):53\u201360","journal-title":"Eur J Intern Med"},{"issue":"5","key":"3153_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"3","key":"3153_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K (2001) A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 29(3):374\u2013393","journal-title":"Sociological Methods & Research"},{"issue":"7","key":"3153_CR24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1177\/0962280216673085","volume":"27","author":"DS Nagin","year":"2018","unstructured":"Nagin DS, Jones BL, Passos VL, Tremblay RE (2018) Group-based multi-trajectory modeling. Stat Methods Med Res 27(7):2015\u20132023","journal-title":"Stat Methods Med Res"},{"key":"3153_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109\u2013138","journal-title":"Annu Rev Clin Psychol"},{"key":"3153_CR26","unstructured":"Schwartz T, Chen Q, Duan N (2011) Studying missing data patterns using a SAS\u00ae Macro. 4:339"},{"issue":"4","key":"3153_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492\u2013499","journal-title":"Am J Epidemiol"},{"key":"3153_CR28","doi-asserted-by":"crossref","unstructured":"Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K, et al (2018) Immortal time bias in observational studies of time-to-event outcomes. Cancer Control [Internet]. [cited 2019 Nov 8];25(1). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6053873\/","DOI":"10.1177\/1073274818789355"},{"issue":"231","key":"3153_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","volume":"15","author":"J Neefs","year":"2017","unstructured":"Neefs J, van den Berg NWE, Limpens J, Berger WR, Boekholdt SM, Sanders P et al (2017) Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 15(231):155\u2013161","journal-title":"Int J Cardiol"},{"key":"3153_CR30","doi-asserted-by":"crossref","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933\u2013989","DOI":"10.1016\/j.ejheart.2008.08.005"},{"issue":"2","key":"3153_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","volume":"53","author":"AF Hernandez","year":"2009","unstructured":"Hernandez AF, Hammill BG, O\u2019Connor CM, Schulman KA, Curtis LH, Fonarow GC (2009) Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 53(2):184\u2013192","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3153_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijcard.2006.07.033","volume":"118","author":"M Peltier","year":"2007","unstructured":"Peltier M, Houpe D, Cohen-Solal A, B\u00e9guin M, Levy F, Tribouilloy C (2007) Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study. Int J Cardiol 118(3):363\u2013369","journal-title":"Int J Cardiol"},{"issue":"2","key":"3153_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","volume":"20","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH (2015) Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 20(2):193\u2013201","journal-title":"Heart Fail Rev"},{"issue":"4","key":"3153_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ehf2.12204","volume":"4","author":"MS Khan","year":"2017","unstructured":"Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M et al (2017) Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 4(4):402\u2013408","journal-title":"ESC Heart Fail"},{"key":"3153_CR35","doi-asserted-by":"crossref","unstructured":"Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT (2018) Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev\u00a028(6):CD012721","DOI":"10.1002\/14651858.CD012721.pub2"},{"issue":"5","key":"3153_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","volume":"104","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO et al (2018) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 104(5):407\u2013415","journal-title":"Heart"},{"key":"3153_CR37","doi-asserted-by":"crossref","unstructured":"Tsujimoto T, Kajio H (2018) Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction. Sci Rep [Internet]. [cited 2020 Apr 23];8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6015007\/","DOI":"10.1038\/s41598-018-27799-y"},{"issue":"19","key":"3153_CR38","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54(19):1747\u20131762","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3153_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","volume":"107","author":"C Tsch\u00f6pe","year":"2018","unstructured":"Tsch\u00f6pe C, Birner C, B\u00f6hm M, Bruder O, Frantz S, Luchner A et al (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the \u201cHeart Failure Working Group\u201d of the German Society of Cardiology (DKG). Clin Res Cardiol 107(1):1\u201319","journal-title":"Clin Res Cardiol"},{"issue":"40","key":"3153_CR40","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","volume":"35","author":"M Senni","year":"2014","unstructured":"Senni M, Paulus WJ, Gavazzi A, Fraser AG, D\u00edez J, Solomon SD et al (2014) New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35(40):2797\u20132815","journal-title":"Eur Heart J"},{"issue":"10","key":"3153_CR41","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.clinthera.2015.08.005","volume":"37","author":"S Nanayakkara","year":"2015","unstructured":"Nanayakkara S, Kaye DM (2015) Management of heart failure with preserved ejection fraction: a review. Clin Ther 37(10):2186\u20132198","journal-title":"Clin Ther"},{"issue":"2","key":"3153_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11739-008-0180-9","volume":"4","author":"G Costantino","year":"2009","unstructured":"Costantino G, Rusconi AM, Duca PG, Guzzetti S, Bossi I, Del Medico M et al (2009) Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern Emerg Med 4(2):117\u2013122","journal-title":"Intern Emerg Med"},{"issue":"7","key":"3153_CR43","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cardfail.2017.04.006","volume":"23","author":"HC Patel","year":"2017","unstructured":"Patel HC, Hayward C, Dungu JN, Papadopoulou S, Saidmeerasah A, Ray R et al (2017) Assessing the eligibility criteria in phase III randomized controlled trials of drug therapy in heart failure with preserved ejection fraction: the critical play-off between a \u201cpure\u201d patient phenotype and the generalizability of trial findings. J Card Fail 23(7):517\u2013524","journal-title":"J Card Fail"},{"key":"3153_CR44","doi-asserted-by":"crossref","unstructured":"Girerd N, Seronde M-F, Coiro S, Chouihed T, Bilbault P, Braun F et al (2018) Integrative assessment of congestion in\u00a0heart failure throughout the patient\u00a0journey. JACC: Heart Failure 6(4):273\u2013285","DOI":"10.1016\/j.jchf.2017.09.023"},{"issue":"1","key":"3153_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jjcc.2019.05.017","volume":"75","author":"F Massari","year":"2020","unstructured":"Massari F, Scicchitano P, Iacoviello M, Passantino A, Guida P, Sanasi M et al (2020) Multiparametric approach to congestion for predicting long-term survival in heart failure. J Cardiol 75(1):47\u201352","journal-title":"J Cardiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T08:09:02Z","timestamp":1631606942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03153-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03153-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}